Parametrica Management Ltd Invests $290,000 in Humana Inc. (NYSE:HUM)

Parametrica Management Ltd bought a new stake in Humana Inc. (NYSE:HUM) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,145 shares of the insurance provider’s stock, valued at approximately $290,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Humana by 15.8% during the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock worth $3,254,899,000 after purchasing an additional 1,751,857 shares during the period. State Street Corp grew its stake in Humana by 1.0% during the third quarter. State Street Corp now owns 5,357,420 shares of the insurance provider’s stock worth $1,701,582,000 after buying an additional 53,272 shares during the period. Pzena Investment Management LLC grew its stake in Humana by 44.0% during the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock worth $915,736,000 after buying an additional 1,103,132 shares during the period. FMR LLC raised its stake in shares of Humana by 23.4% in the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after acquiring an additional 643,291 shares during the period. Finally, Sanders Capital LLC lifted its holdings in shares of Humana by 1.0% during the 3rd quarter. Sanders Capital LLC now owns 1,168,341 shares of the insurance provider’s stock valued at $370,060,000 after acquiring an additional 11,923 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.37% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have commented on HUM. JPMorgan Chase & Co. cut their price objective on Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 18th. Barclays upped their price target on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a report on Thursday, February 13th. Cantor Fitzgerald reissued a “neutral” rating and set a $290.00 target price on shares of Humana in a research report on Wednesday, February 12th. Morgan Stanley decreased their target price on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. Finally, Truist Financial lifted their price target on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Eighteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $285.68.

Humana Stock Performance

Shares of NYSE HUM opened at $273.51 on Wednesday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm’s 50-day moving average price is $270.83 and its two-hundred day moving average price is $275.00. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The stock has a market capitalization of $33.01 billion, a P/E ratio of 27.49, a P/E/G ratio of 2.05 and a beta of 0.57.

Humana (NYSE:HUM) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, sell-side analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.29%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s payout ratio is 35.58%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.